0001209191-17-041632.txt : 20170623
0001209191-17-041632.hdr.sgml : 20170623
20170623160504
ACCESSION NUMBER: 0001209191-17-041632
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170621
FILED AS OF DATE: 20170623
DATE AS OF CHANGE: 20170623
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CELGENE CORP /DE/
CENTRAL INDEX KEY: 0000816284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 222711928
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
BUSINESS PHONE: (908)673-9000
MAIL ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CASEY MICHAEL D
CENTRAL INDEX KEY: 0001190435
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34912
FILM NUMBER: 17927616
MAIL ADDRESS:
STREET 1: ALLOS THERAPEUTICS, INC.
STREET 2: 11080 CIRCLEPOINT ROAD, SUITE 200
CITY: WESTMINSTER
STATE: CO
ZIP: 80020
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-06-21
0
0000816284
CELGENE CORP /DE/
CELG
0001190435
CASEY MICHAEL D
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT
NJ
07901
1
0
0
0
Common Stock
2017-06-21
4
M
0
9250
33.88
A
9250
D
Common Stock
2017-06-21
4
S
0
9250
133.05
D
0
D
Common Stock
92070
I
Family Trust
Stock Option (right to buy)
33.88
2017-06-21
4
M
0
9250
0.00
D
2027-09-17
Common Stock
9250
0
D
The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $132.68 to $133.19, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The option was fully exercisable.
The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.
/s/ Mark J. Alles, Attorney-in-Fact
2017-06-23